EHMT2 and neoplasm: Finally, EHMT2 and TGF-β1 inhibitors reduced tumor growth, identifying EHMT2 as a promising, druggable target that suppresses NK cell-mediated anti-tumor immunity via TGF-β1-mediated autocrine and paracrine effects (Fig. 8L).